CN1762455A - Chinese medicinal formulation for treating infant lung and stomach exuberance heat - Google Patents
Chinese medicinal formulation for treating infant lung and stomach exuberance heat Download PDFInfo
- Publication number
- CN1762455A CN1762455A CN 200510104940 CN200510104940A CN1762455A CN 1762455 A CN1762455 A CN 1762455A CN 200510104940 CN200510104940 CN 200510104940 CN 200510104940 A CN200510104940 A CN 200510104940A CN 1762455 A CN1762455 A CN 1762455A
- Authority
- CN
- China
- Prior art keywords
- radix
- solution
- preparation
- reference substance
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004072 lung Anatomy 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 title claims abstract description 11
- 210000002784 stomach Anatomy 0.000 title claims abstract description 11
- 238000009472 formulation Methods 0.000 title abstract description 3
- 239000007788 liquid Substances 0.000 claims abstract description 57
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 239000011505 plaster Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 108
- 239000000243 solution Substances 0.000 claims description 59
- 239000003814 drug Substances 0.000 claims description 44
- 238000012360 testing method Methods 0.000 claims description 38
- 238000002360 preparation method Methods 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 30
- 239000013558 reference substance Substances 0.000 claims description 30
- 239000000341 volatile oil Substances 0.000 claims description 23
- 239000000706 filtrate Substances 0.000 claims description 22
- 239000000796 flavoring agent Substances 0.000 claims description 22
- 235000019634 flavors Nutrition 0.000 claims description 22
- 238000012546 transfer Methods 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 15
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 14
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 14
- 229960003321 baicalin Drugs 0.000 claims description 14
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 14
- 239000010231 banlangen Substances 0.000 claims description 13
- 239000003921 oil Substances 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 12
- 229920000053 polysorbate 80 Polymers 0.000 claims description 12
- 229930006000 Sucrose Natural products 0.000 claims description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 11
- 239000005720 sucrose Substances 0.000 claims description 11
- 239000003208 petroleum Substances 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 239000012567 medical material Substances 0.000 claims description 9
- 238000004321 preservation Methods 0.000 claims description 9
- 238000004064 recycling Methods 0.000 claims description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 claims description 8
- 239000000741 silica gel Substances 0.000 claims description 8
- 229910002027 silica gel Inorganic materials 0.000 claims description 8
- 238000004809 thin layer chromatography Methods 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 7
- 230000006837 decompression Effects 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000014759 maintenance of location Effects 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- -1 electuary Substances 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000010282 Emodin Substances 0.000 claims description 3
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 claims description 3
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 claims description 3
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 claims description 3
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims description 3
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 claims description 3
- 229960000583 acetic acid Drugs 0.000 claims description 3
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 claims description 3
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 claims description 3
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 claims description 3
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 claims description 3
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 2
- IBPFZCOJYVDKGN-UHFFFAOYSA-N OC.OC=O.ClC(Cl)Cl.CCOC(C)=O Chemical compound OC.OC=O.ClC(Cl)Cl.CCOC(C)=O IBPFZCOJYVDKGN-UHFFFAOYSA-N 0.000 claims description 2
- 230000000274 adsorptive effect Effects 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000002662 enteric coated tablet Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 239000012362 glacial acetic acid Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 2
- JWHHANVGNNWIRI-UHFFFAOYSA-N methanol phosphoric acid hydrate Chemical compound O.OC.OP(O)(O)=O JWHHANVGNNWIRI-UHFFFAOYSA-N 0.000 claims description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000003908 quality control method Methods 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 238000011003 system suitability test Methods 0.000 claims description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 2
- 235000012141 vanillin Nutrition 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 238000004811 liquid chromatography Methods 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 abstract description 5
- 241000931705 Cicada Species 0.000 abstract 1
- 241000758993 Equisetidae Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 240000002505 Pogostemon cablin Species 0.000 abstract 1
- 235000011751 Pogostemon cablin Nutrition 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 241001530126 Scrophularia Species 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 239000004575 stone Substances 0.000 abstract 1
- 238000000605 extraction Methods 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 238000005352 clarification Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930194248 Licoflavone Natural products 0.000 description 1
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- LNOHXHDWGCMVCO-UHFFFAOYSA-N Wogonoside Natural products C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1OC1OC(C(O)=O)C(O)C(O)C1O LNOHXHDWGCMVCO-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002338 glycosides Chemical group 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229930014456 matrine Natural products 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229930015582 oxymatrine Natural products 0.000 description 1
- 239000009835 oxypaeoniflora Substances 0.000 description 1
- FCHVXNVDFYXLIL-QYDSDWLYSA-N oxypaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=C(O)C=C1 FCHVXNVDFYXLIL-QYDSDWLYSA-N 0.000 description 1
- RLXWQODPAWIVOI-UHFFFAOYSA-N oxypaeoniflorin Natural products OCC1OC(OC23CC4C5(O)CC2OC(O5)C34COC(=O)c6ccc(O)cc6)C(O)C(O)C1O RLXWQODPAWIVOI-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- ZAVXXBAIPSQJGS-UHFFFAOYSA-B tetracalcium;tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ZAVXXBAIPSQJGS-UHFFFAOYSA-B 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- LNOHXHDWGCMVCO-NTKSAMNMSA-N wogonin 7-O-beta-D-glucuronide Chemical compound C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LNOHXHDWGCMVCO-NTKSAMNMSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a Chinese medicinal formulation for treating infant lung and stomach exuberance heat, which is prepared from the following raw materials: baikal skullcap root, patchouli, cicada shell, plaster stone, kudzu vine root, rhubarb horsetails, radix paeoniae rubrathe, isatic root, root of ballon flower, scrophularia root, subprostrate sophora root, licorice root, the preferred dosage form is oral liquid.
Description
Technical field:
The present invention relates to a kind of Chinese medicine preparation, be particularly related to the Chinese medicine preparation of treatment infant lung and stomach exuberance heat, said preparation is made by following raw material of Chinese medicine: Radix Scutellariae, Herba Pogostemonis, Periostracum Cicadae, Gypsum Fibrosum, Radix Puerariae, Radix Et Rhizoma Rhei, Radix Paeoniae Rubra, Radix Isatidis, Radix Platycodonis, Radix Scrophulariae, Radix Sophorae Tonkinensis, Radix Glycyrrhizae.
Background technology:
Infant lung and stomach exuberance heat is a common disease in children disease, symptoms such as heating, headache, thirsty, dry pharynx pain, agitation, cough, abdominal distention constipation, yellowish urine, red tongue with yellow fur, slippery and rapid pulse are arranged more, in recent years, along with going deep into of clinical research, the medicine that also occurs some treatment infant lung and stomach exuberance heats on the market, existing medicine belongs to a bit cures the symptoms, not the disease, and some uses expensive composition, and some is cut and interrupt using owing to uncertain therapeutic efficacy in application process.
In view of this, the inventor develop a kind of taking convenience, effect steadily, determined curative effect, dosage form is stable, quality controllable and the pure Chinese medicinal preparation of the treatment infant lung and stomach exuberance heat that has no side effect, to satisfy the demand of extensive patients.
Summary of the invention:
The invention provides a kind of pure Chinese medicinal preparation for the treatment of infant lung and stomach exuberance heat, said preparation is made by following Chinese medicine raw materials by weight proportion:
Radix Scutellariae 50-200g Herba Pogostemonis 40-160g Periostracum Cicadae 20-80g Gypsum Fibrosum 100-400g
Radix Puerariae 40-160g Radix Et Rhizoma Rhei 20-80g Radix Paeoniae Rubra 40-160g Radix Isatidis 40-160g
Radix Platycodonis 40-160g Radix Scrophulariae 40-160g Radix Sophorae Tonkinensis 40-160g Radix Glycyrrhizae 30-120g
Preferably:
Radix Scutellariae 75-133g Herba Pogostemonis 60-106g Periostracum Cicadae 30-53g Gypsum Fibrosum 150-266g
Radix Puerariae 60-106g Radix Et Rhizoma Rhei 30-53g Radix Paeoniae Rubra 60-106g Radix Isatidis 60-106g
Radix Platycodonis 60-106g Radix Scrophulariae 60-106g Radix Sophorae Tonkinensis 60-106g Radix Glycyrrhizae 45-80g
Most preferably:
Radix Scutellariae 100g Herba Pogostemonis 80g Periostracum Cicadae 40g Gypsum Fibrosum 200g
Radix Puerariae 80g Radix Et Rhizoma Rhei 40g Radix Paeoniae Rubra 80g Radix Isatidis 80g
Radix Platycodonis 80g Radix Scrophulariae 80g Radix Sophorae Tonkinensis 80g Radix Glycyrrhizae 60g
In more than forming, the weight of each medicine of distinguishing the flavor of is calculated with crude drug, and above-mentioned prescription composition can be made into 1000 doses of pharmaceutical preparatioies.Described 1 dose of finger, the final drug preparation of making, as make 1000 of capsule preparations, 1000 in tablet, granule 1000 grams, oral liquid 1000ml etc.
More than form to be by weight as proportioning, when producing, can increase or reduce according to corresponding proportion, as large-scale production can be unit with the kilogram, or be unit with the ton, small-scale production can be unit with the milligram also, weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion obtains through science screening, for especial patient, and as serious symptom or light disease, fat or modest patient, the proportioning of the amount of can corresponding adjustment forming increases or reduces being no more than 100%, and drug effect is constant.
Raw material of Chinese medicine, especially adjuvant drug in more than forming can be replaced with the suitable Chinese medicine with identical property of medicine with messenger drug, and its drug effect of the Chinese medicine preparation after the replacement is constant.
Chinese medicine preparation of the present invention is to process through extraction or other modes by the raw material of Chinese medicine that above-mentioned prescription is formed, and makes pharmaceutically active substance, subsequently, with this material is raw material, adds the medicine acceptable carrier when needing, and makes according to the routine techniques of galenic pharmacy.Described active substance can obtain by extracting raw material of Chinese medicine respectively, also can obtain by the co-extracted raw material of Chinese medicine, also can obtain by other modes, as: by pulverize, squeeze, calcine, grind, sieve, percolation, extraction, water are carried, alcohol extraction, ester are carried, methods such as ketone is carried, chromatography obtain, these active substances can be the material of extractum form, can be that dry extract also can be a fluid extract, make different concentration according to the different needs decision of preparation.
Pharmaceutical preparation of the present invention, the pharmaceutical dosage forms of unit dose preferably, can make any pharmaceutically useful dosage form when making pharmaceutical preparation, these dosage forms are selected from: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch.Preferably oral liquid form, most preferably oral liquid.
Pharmaceutical preparation of the present invention, pharmaceutically active substance makes through extracting processing, and processing method is as follows:
More than 12 flavors, get Herba Pogostemonis and extract volatile oil, standby, carry the medicinal liquid behind the oil, in addition device is stored, medicinal residues with all the other ten simply medical material decoct with water, add the merging decoction liquor when wherein Radix Scutellariae boils, filter, merge with above-mentioned medicinal liquid, concentrating under reduced pressure is transferred pH, add ethanol, leave standstill, filter filtrate recycling ethanol, add water, transfer pH, cold preservation, filter, get filtrate, this filtrate and volatile oil are pharmaceutically active substance of the present invention together.This active substance mixes with the medicine acceptable carrier, promptly can be made into pharmaceutical preparation of the present invention according to the galenic pharmacy routine techniques.
The preparation method of oral liquid can be:
More than 12 flavors, get Herba Pogostemonis and extract volatile oil, standby, carry the medicinal liquid behind the oil, device is stored in addition, medicinal residues with all the other ten simply medical material add 10 times of water gagings decoctions three times, add when wherein Radix Scutellariae boils, each 1 hour, merge decoction liquor, filter, merge, be evaporated to relative density 1.10 (40 ℃) with above-mentioned medicinal liquid, transfer pH5.5, add ethanol, make to contain the alcohol amount and reach 70%, leave standstill, filter, decompression filtrate recycling ethanol is to there not being the alcohol flavor, add water to about 900ml, transfer pH7.0, cold preservation, filter, filtrate adds sucrose 100g, boils, put when being chilled to about 40 ℃, stir the mixed liquor that adds Tween 80 3ml and volatile oil 0.5ml down, add water to be adjusted to 1000ml, transfer pH to 7.0, filter, fill, sterilization, promptly.
Pharmaceutical preparation of the present invention can add some medicine acceptable carriers as required, can adopt the galenic pharmacy routine techniques to prepare this pharmaceutical preparation, as pharmaceutically active substance is mixed with the medicine acceptable carrier.Described medicine acceptable carrier is selected from: mannitol, sorbitol, sorbic acid or potassium salt, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin A, vitamin C, vitamin E, vitamin D, azone, the EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, propylene glycol, ethanol, soil temperature 60-80, span-80, Cera Flava, lanoline, liquid paraffin, hexadecanol, gallate ester, agar, triethanolamine, basic amino acid, carbamide, allantoin, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Pharmaceutical preparation of the present invention is determined usage and dosage according to patient's situation in use.
Pharmaceutical composition of the present invention, when making medicament, the medicament of unit dose can contain pharmaceutically active substance 0.1-1000mg of the present invention, and all the other are pharmaceutically acceptable carrier.Pharmaceutically acceptable carrier can be the 0.1-99.9% of total formulation weight amount by weight.
The most preferred prescription of the present invention is listed in the embodiment of the invention.
Technology of the present invention obtains through screening, according to as follows:
Herba Pogostemonis contains volatile ingredient, extracts volatile oil with the way of distillation, its water soluble ingredient water boiling and extraction.
Contain the active component flavonoid in the Radix Scutellariae: baicalin, wogonoside etc., relevant extracting method report is more, and is better because of its water solublity, adopts water extraction.Monarch drug in the Radix Scutellariae side of being, baicalin has effects such as antibiotic, analgesic, is index so select the content with baicalin, and process conditions are carried out preferably.
Contain flavones ingredient in the Radix Puerariae: puerarin, daidzein, daidzin etc., not only water-soluble but also be dissolved in alcohol.
According to bibliographical information, Radix Glycyrrhizae contains glycyrrhizic acid, enoxolone, licoflavone etc.; Radix Platycodonis contains kikyosaponin, glycoside unit etc.; Radix Paeoniae Rubra contains paeoniflorin, oxypaeoniflorin; Radix Scrophulariae contains Radix Scrophulariae element, iridoids etc.; Radix Sophorae Tonkinensis contains matrine, oxymatrine etc.; Radix Et Rhizoma Rhei contains chrysophanic acid, chrysophanol, emodin etc.; Periostracum Cicadae contains aminoacid etc., and these compositions all have certain dissolubility in water and alcohol, so the method that adopts decocting to boil is extracted.
The Gypsum Fibrosum main component is a calcium sulfate, and being decocted first to fry in shallow oil for a long time to increase content, closes to fry in shallow oil in compound recipe to be better than singly frying in shallow oil, so adopt the technology of frying in shallow oil altogether.
Radix Isatidis contains indirubin, composition such as indigo, and the extracting method report is more.We result of the test show, and are similar with the content of indirubin in the oral liquid that water extraction process is made with ethanol extraction technology, so adopt with water extraction.
The present invention determines with the method that decocting boils its main effective ingredient to be extracted, but also extract water-solubility impurity in the time of with water boiling and extraction, remove with ethanol precipitation,, process conditions are carried out preferably by orthogonal test so the present invention is to be the basic technology route with the water extract-alcohol precipitation.
The present invention selects respective carrier when making oral liquid, and is as follows as the selection of sweeting agent, solubilizing agent:
For regulating mouthfeel, selected sucrose as sweeting agent, the solution that is made into variable concentrations compares, evidence, sucrose concentration is 10% o'clock, and sugariness is moderate, and viscosity is suitable, and mouthfeel is better, the results are shown in Table 1.
The selection of sweeting agent consumption in table 1 oral liquid
| Sucrose % (g/ml) | 5 | 10 | 15 | 20 |
| The mouthfeel viscosity | The heavier variation of bitterness is not obvious | Bitterness is thickness more slightly | Bitterness is arranged slightly than thickness | The bitterness thickness is arranged slightly |
Herba Pogostemonis Volatile oil is insoluble in water in the prescription, selects for use Tween 80 to do solubilizing agent, gets not commensurability Tween 80, mixes the back with volatile oil and adds medicinal liquid, and result of the test shows: the consumption of Tween 80 is advisable with 0.3%, the results are shown in Table 2.
The Tween 80 consumption is selected in table 2 oral liquid
| Tween 80 % (ml/ml) | 0.1 | 0.2 | 0.3 | 0.4 | 0.5 | 0.6 |
| The clarity mouthfeel | Better muddy | Muddiness has abnormal flavour slightly | Clarification has abnormal flavour slightly | Clarification has abnormal flavour | The clarification abnormal flavour is dense | The clarification abnormal flavour is dense |
(3). the dosing prescription
According to above test, determine that oral liquid dosing prescription is:
Extracting solution 900ml sucrose 100g Herba Pogostemonis Volatile oil 0.5ml Tween 80 3ml makes 1000ml
The present invention also comprises the method for quality control of preparation of the present invention, particularly oral liquid, and this method comprises: contents such as character, discriminating, inspection, assay, specifically:
[character] this oral liquid is the supernatant liquid of rufous, and postpone for a long time can have microprecipitation, sweet, little hardship of distinguishing the flavor of.
This oral liquid 20ml is got in [discriminating] (1), with petroleum ether (30-60 ℃) extraction 4 times, each 30ml, merge extractive liquid, reclaims petroleum ether, and residue adds petroleum ether (60-90 ℃) 2ml makes dissolving, as need testing solution, other gets Bai Qiuli alcohol reference substance, adds ethyl acetate and makes the solution that every 1ml contains 1mg, in contrast product solution.Test according to thin layer chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000), draw need testing solution 10 μ l, reference substance solution 2 μ l, putting respectively on same silica gel g thin-layer plate, is developing solvent with petroleum ether (30-60 ℃)-ethyl acetate-glacial acetic acid (95: 5: 0.2), launches, take out, dry, spray is with 5% ferric chloride alcoholic solution, and hot blast blows to clear spot.In the test sample chromatograph, with reference substance chromatograph relevant position on, show the same color speckle.
(2) get this oral liquid 20ml, be added in AB-8 type macroporous adsorptive resins (the internal diameter 1.5cm that has handled well, long 12cm) successively with water 100ml, 20% ethanol 100ml eluting, discard eluent, reuse 50% ethanol 100ml eluting, eluent evaporate to dryness, residue adds methanol 2ml dissolving, as need testing solution.Other gets the puerarin reference substance, adds methanol and makes the solution that every 1ml contains 1mg, in contrast product solution.Test according to thin layer chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000), draw need testing solution 6 μ l, reference substance solution 4 μ l, putting respectively on same silica gel g thin-layer plate, is developing solvent with chloroform-methanol-water (14: 5: 0.5), launches, take out, dry, after the ammonia steam is smoked, to ultra-violet lamp (365nm), inspect.In the test sample chromatograph, with contrast chromatograph corresponding position on, show the fluorescence speckle of same color.
(3) get the paeoniflorin reference substance, add ethanol and make the solution that every 1ml contains 1mg, in contrast product solution.Test according to thin layer chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000), draw the need testing solution 6 μ l respectively under above-mentioned reference substance solution and [discriminatings] (2) respectively, put respectively on same silica gel g thin-layer plate, with chloroform-ethyl acetate-methanol-formic acid (40: 5: 10: 0.2) be developing solvent, launch, take out, dry, spray is with 5% vanillin sulfuric acid solution, hot blast blows to clear spot, in the test sample chromatograph, with reference substance chromatograph relevant position on, show identical bluish violet speckle.
(4) get this oral liquid 20ml, add hydrochloric acid 3ml, heated 30 minutes to water-bath, extracted with diethyl ether 3 times are used in cooling immediately, and each 30ml merges ether solution, and low temperature volatilizes ether, and residue adds chloroform 2ml and dissolves, as need testing solution.Other gets emodin reference substance and chrysophanol reference substance, add methanol respectively and make the solution that every 1ml contains 1mg, product solution according to thin layer chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000) test, is drawn each 6 μ l of above-mentioned three kinds of solution in contrast, put respectively on same silica gel g thin-layer plate, with petroleum ether (30-60 ℃)-Ethyl formate (15: 5) is developing solvent, launches, and takes out, dry, to ultra-violet lamp (365nm), inspect.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show identical orange-yellow fluorescence speckle.After the ammonia steam is smoked, to daylight, to inspect, speckle becomes redness.
(5) this oral liquid retention time in the gained chromatograph under the assay item should be consistent with the retention time of reference substance.
[inspection] relative density should be not less than 1.05 (appendix VIIA of Chinese Pharmacopoeia version in 2000).
PH value should be 4.5-7.0 (appendix VIIA of Chinese Pharmacopoeia version in 2000).
Other should meet every regulation relevant under the mixture item (appendix IJ of Chinese Pharmacopoeia version in 2000).
[assay] measured according to high performance liquid chromatography (appendix VID).
Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; Methanol-water-phosphoric acid (47: 53: 0.2) is a mobile phase, and the detection wavelength is 280nm.Number of theoretical plate is pressed the baicalin peak and is calculated, and should be not less than 2500.
It is an amount of that the preparation precision of reference substance solution takes by weighing the baicalin reference substance, adds 70% ethanol and make the solution that every 1ml contains 18 μ g, in contrast product solution.
The accurate this product 5ml that draws of the preparation of need testing solution puts in the 100ml measuring bottle, adds 70% ethanol dilution to scale, shakes up.The accurate 1.0ml that draws puts in the 10ml measuring bottle, adds 70% ethanol dilution to scale, shakes up, as need testing solution.
Accurate respectively reference substance and each the 10 μ l injection chromatograph of liquid of need testing solution drawn of algoscopy measured promptly.
This oral liquid contains Radix Scutellariae must not be less than 3.0mg/ml in baicalin.
Pharmaceutical preparation of the present invention, its function are dispelling wind and heat pathogens, clearing interior heat, heat-clearing and toxic substances removing, relieving sore throat and pain with curing mainly.Be applicable to the card of infant lung and stomach exuberance heat.Cure mainly diseases such as heating, headache, thirsty, dry pharynx pain, agitation, cough, abdominal distention constipation, yellowish urine, red tongue with yellow fur, slippery and rapid pulse.
Chinese medicine preparation of the present invention, its prescription composition complements each other, and has synergism, and therapeutic effect is good, and few side effects is suitable for child administration.
Chinese medicine preparation of the present invention, particularly oral liquid, its usage and consumption are: oral 2-3 time on the 1st, 2 years old with interior 5ml, 2-4 year 5-10ml, 4-6 year 10-15ml, 15-20ml more than six years old, or follow the doctor's advice.
The specific embodiment:
Further specify the present invention by the following examples, but not as limitation of the present invention.
Embodiment 1
Prescription:
Radix Scutellariae 1000g Herba Pogostemonis 800g Periostracum Cicadae 400g Gypsum Fibrosum 2000g
Radix Puerariae 800g Radix Et Rhizoma Rhei 400g Radix Paeoniae Rubra 800g Radix Isatidis 800g
Radix Platycodonis 800g Radix Scrophulariae 800g Radix Sophorae Tonkinensis 800g Radix Glycyrrhizae 600g
The dosing prescription:
Extracting solution 9000ml Herba Pogostemonis Volatile oil 5ml
Sucrose 1000g Tween 80 30ml
Make 10000ml
More than 12 flavors, get Herba Pogostemonis and extract volatile oil, standby, carry the medicinal liquid behind the oil, device is stored in addition, medicinal residues with all the other ten simply medical material add 10 times of water gagings decoctions three times, add when wherein Radix Scutellariae boils, each 1 hour, merge decoction liquor, filter, merge, be evaporated to relative density 1.10 (40 ℃) with above-mentioned medicinal liquid, transfer pH5.5, add ethanol, make to contain the alcohol amount and reach 70%, leave standstill, filter, decompression filtrate recycling ethanol is to there not being the alcohol flavor, add water to about 900ml, transfer pH7.0, cold preservation, filter, filtrate adds sucrose 100g, boils, put when being chilled to about 40 ℃, stir the mixed liquor that adds Tween 80 3ml and volatile oil 0.5ml down, add water to be adjusted to 1000ml, transfer pH to 7.0, filter, fill, sterilization, promptly.
10,000 milliliters every batch, totally three batches.The data result of each link and discriminating in the relevant preparation process, quality examination and assay (measuring with the HPLC method) the results are shown in Table 3.
The result shows that the content of the discriminating of three batches of oral liquids, clarity, content uniformity, pH value, relative density, limit test of microbe and baicalin (using high-performance liquid chromatogram determination) is all up to specification.
The fragrant removing summer-heat oral liquid of table 3 a kind of reed mentioned in ancient books pilot scale creation data table
| Lot number | 960518 | 960611 | 960627 |
| The content % decocting liquid of radix scutellariae medicinal materials baicalin concentrates relative density precipitate with ethanol pH value alcohol precipitation concentration, (%) baicalin content before the fill of medicinal liquid pH value, (mlg/ml) | 8.14 1.13 5.52 70 7.0 3.21 | 9.13 1.10 5.50 70 7.0 3.78 | 9.13 1.12 5.53 70 7.0 4.03 |
| Finished product number (propping up) yield rate (%) is differentiated clarity relative density loading amount (ml) pH value baicalin content (mg/ml) baicalin retention rate (%) microorganism checking | 908 95.35 are positive reaction clarifies 1.110 10 5.53 3.06 37.59 and up to specificationly sees attached list 4 | 916 96.18 are positive reaction clarifies 1.116 10 5.53 3.67 40.20 and up to specificationly sees attached list 5 | 919 96.53 are positive reaction clarifies 1.110 10 5.48 4.00 43.81 and up to specificationly sees attached list 6 |
Embodiment 2
Radix Scutellariae 50g Herba Pogostemonis 40g Periostracum Cicadae 20g Gypsum Fibrosum 100g
Radix Puerariae 40g Radix Et Rhizoma Rhei 20g Radix Paeoniae Rubra 40g Radix Isatidis 40g
Radix Platycodonis 40g Radix Scrophulariae 40g Radix Sophorae Tonkinensis 40g Radix Glycyrrhizae 30g
More than 12 flavors, get Herba Pogostemonis and extract volatile oil, standby, carry the medicinal liquid behind the oil, device is stored in addition, medicinal residues with all the other ten simply medical material add 10 times of water gagings decoctions three times, add when wherein Radix Scutellariae boils, each 1 hour, merge decoction liquor, filter, merge, be evaporated to relative density 1.10 (40 ℃) with above-mentioned medicinal liquid, transfer pH5.5, add ethanol, make to contain the alcohol amount and reach 70%, leave standstill, filter, decompression filtrate recycling ethanol is to there not being the alcohol flavor, add water to about 900ml, transfer pH7.0, cold preservation, filter, filtrate adds sucrose 100g, boils, put when being chilled to about 40 ℃, stir the mixed liquor that adds Tween 80 3ml and volatile oil 0.5ml down, add water to be adjusted to 1000ml, transfer pH to 7.0, filter, fill, sterilization, promptly.
Embodiment 3
Radix Scutellariae 200g Herba Pogostemonis 160g Periostracum Cicadae 80g Gypsum Fibrosum 400g
Radix Puerariae 160g Radix Et Rhizoma Rhei 80g Radix Paeoniae Rubra 160g Radix Isatidis 160g
Radix Platycodonis 160g Radix Scrophulariae 160g Radix Sophorae Tonkinensis 160g Radix Glycyrrhizae 120g
More than 12 flavors, get Herba Pogostemonis and extract volatile oil, standby, carry the medicinal liquid behind the oil, device is stored in addition, medicinal residues with all the other ten simply medical material add 10 times of water gagings decoctions three times, add when wherein Radix Scutellariae boils, each 1 hour, merge decoction liquor, filter, merge, be evaporated to relative density 1.10 (40 ℃) with above-mentioned medicinal liquid, transfer pH5.5, add ethanol, make to contain the alcohol amount and reach 70%, leave standstill, filter, decompression filtrate recycling ethanol is to there not being the alcohol flavor, add water to about 900ml, transfer pH7.0, cold preservation, filter, filtrate adds sucrose 100g, boils, put when being chilled to about 40 ℃, stir the mixed liquor that adds Tween 80 3ml and volatile oil 0.5ml down, add water to be adjusted to 1000ml, transfer pH to 7.0, filter, fill, sterilization, promptly.
Embodiment 4
Radix Scutellariae 100g Herba Pogostemonis 80g Periostracum Cicadae 40g Gypsum Fibrosum 200g
Radix Puerariae 80g Radix Et Rhizoma Rhei 40g Radix Paeoniae Rubra 80g Radix Isatidis 80g
Radix Platycodonis 80g Radix Scrophulariae 80g Radix Sophorae Tonkinensis 80g Radix Glycyrrhizae 60g
More than 12 flavors, get Herba Pogostemonis and extract volatile oil, standby, carry the medicinal liquid behind the oil, device is stored in addition, medicinal residues with all the other ten simply medical material add 10 times of water gagings decoctions three times, add when wherein Radix Scutellariae boils, each 1 hour, merge decoction liquor, filter, merge, be evaporated to relative density 1.10 (40 ℃) with above-mentioned medicinal liquid, transfer pH5.5, add ethanol, make to contain the alcohol amount and reach 70%, leave standstill, filter, decompression filtrate recycling ethanol is to there not being the alcohol flavor, add water to about 900ml, transfer pH7.0, cold preservation, filter, get filtrate, this filtrate and volatile oil are pharmaceutically active substance together, add an amount of dextrin therein, starch, alcohol granulation, Pulvis Talci is a lubricant, and tabletting gets tablet.
Embodiment 5
Radix Scutellariae 100g Herba Pogostemonis 80g Periostracum Cicadae 40g Gypsum Fibrosum 200g
Radix Puerariae 80g Radix Et Rhizoma Rhei 40g Radix Paeoniae Rubra 80g Radix Isatidis 80g
Radix Platycodonis 80g Radix Scrophulariae 80g Radix Sophorae Tonkinensis 80g Radix Glycyrrhizae 60g
More than 12 flavors, get Herba Pogostemonis and extract volatile oil, standby, carry the medicinal liquid behind the oil, device is stored in addition, medicinal residues with all the other ten simply medical material add 10 times of water gagings decoctions three times, add when wherein Radix Scutellariae boils, each 1 hour, merge decoction liquor, filter, merge, be evaporated to relative density 1.10 (40 ℃) with above-mentioned medicinal liquid, transfer pH5.5, add ethanol, make to contain the alcohol amount and reach 70%, leave standstill, filter, decompression filtrate recycling ethanol is to there not being the alcohol flavor, add water to about 900ml, transfer pH7.0, cold preservation, filter, get filtrate, this filtrate and volatile oil are pharmaceutically active substance together, add an amount of dextrin therein, starch, alcohol granulation, magnesium stearate is lubricant, and is encapsulated, obtains capsule.
Claims (10)
1, a kind of Chinese medicine preparation for the treatment of infant lung and stomach exuberance heat is characterized in that, said preparation is made by following Chinese medicine raw materials by weight proportion:
Radix Scutellariae 50-200g Herba Pogostemonis 40-160g Periostracum Cicadae 20-80g Gypsum Fibrosum 100-400g
Radix Puerariae 40-160g Radix Et Rhizoma Rhei 20-80g Radix Paeoniae Rubra 40-160g Radix Isatidis 40-160g
Radix Platycodonis 40-160g Radix Scrophulariae 40-160g Radix Sophorae Tonkinensis 40-160g Radix Glycyrrhizae 30-120g
2, the Chinese medicine preparation of claim 1 is characterized in that, said preparation is made by following Chinese medicine raw materials by weight proportion:
Radix Scutellariae 75-133g Herba Pogostemonis 60-106g Periostracum Cicadae 30-53g Gypsum Fibrosum 150-266g
Radix Puerariae 60-106g Radix Et Rhizoma Rhei 30-53g Radix Paeoniae Rubra 60-106g Radix Isatidis 60-106g
Radix Platycodonis 60-106g Radix Scrophulariae 60-106g Radix Sophorae Tonkinensis 60-106g Radix Glycyrrhizae 45-80g
3, the Chinese medicine preparation of claim 1 is characterized in that, said preparation is made by following Chinese medicine raw materials by weight proportion:
Radix Scutellariae 100g Herba Pogostemonis 80g Periostracum Cicadae 40g Gypsum Fibrosum 200g
Radix Puerariae 80g Radix Et Rhizoma Rhei 40g Radix Paeoniae Rubra 80g Radix Isatidis 80g
Radix Platycodonis 80g Radix Scrophulariae 80g Radix Sophorae Tonkinensis 80g Radix Glycyrrhizae 60g
4. any one Chinese medicine preparation of claim 1-3 is selected from: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch.
5. the Chinese medicine preparation of claim 4 is oral liquids.
6. the Chinese medicine preparation of claim 1 wherein also comprises the medicine acceptable carrier.
7. the application of the Chinese medicine preparation of claim 1 in the medicine of preparation treatment infant lung and stomach exuberance heat card.
8, the preparation method of the Chinese medicine preparation of claim 1 is characterized in that, the process following steps: get Herba Pogostemonis and extract volatile oil, standby, carry the medicinal liquid behind the oil, device is stored in addition, medicinal residues and all the other ten medical material simply decoct with water, and add when wherein Radix Scutellariae boils, and merge decoction liquor, filter, merge concentrating under reduced pressure with above-mentioned medicinal liquid, transfer pH, add ethanol, leave standstill, filter, filtrate recycling ethanol adds water, transfers pH, cold preservation, filter, get filtrate, this filtrate and volatile oil are pharmaceutically active substance together, this active substance mixes with the medicine acceptable carrier, makes pharmaceutical preparation of the present invention according to the galenic pharmacy routine techniques.
9, preparation method according to Claim 8 is characterized in that, the process following steps of purchasing of oral liquid formulation wherein: get Herba Pogostemonis and extract volatile oil, standby, carry the medicinal liquid behind the oil, device is stored in addition, medicinal residues and all the other ten medical material simply add 10 times of water gagings and decoct three times, add each 1 hour when wherein Radix Scutellariae boils, merge decoction liquor, filter, merge with above-mentioned medicinal liquid, be evaporated to relative density 1.10, transfer pH5.5, add ethanol, make to contain alcohol amount and reach 70%, leave standstill, filter, decompression filtrate recycling ethanol adds water to about 900ml to there not being the alcohol flavor, transfers pH7.0, cold preservation filters, and filtrate adds sucrose 100g, boil, put when being chilled to about 40 ℃, stir the mixed liquor that adds Tween 80 3ml and volatile oil 0.5ml down, add water and be adjusted to 1000ml, transfer pH to 7.0, filter fill, sterilization, promptly.
10, the method for quality control of the pharmaceutical preparation of claim 5 is characterized in that, comprises following content, character, discriminating, inspection, assay, wherein
Theing contents are as follows of character
This oral liquid is the supernatant liquid of rufous, and postpone for a long time can have microprecipitation, sweet, little hardship of distinguishing the flavor of; That differentiates thes contents are as follows:
(1) gets this oral liquid 20ml, use petroleum ether, extract 4 times, each 30ml, merge extractive liquid, reclaims petroleum ether, residue adds petroleum ether, and 2ml makes dissolving, as need testing solution, other gets Bai Qiuli alcohol reference substance, add ethyl acetate and make the solution that every 1ml contains 1mg, product solution is tested according to thin layer chromatography in contrast, draw need testing solution 10 μ l, reference substance solution 2 μ l put respectively on same silica gel g thin-layer plate, with petroleum ether-ethyl acetate-glacial acetic acid, be developing solvent, launch, take out, dry, spray is with 5% ferric chloride alcoholic solution, and hot blast blows to clear spot.In the test sample chromatograph, with reference substance chromatograph relevant position on, show the same color speckle;
(2) get this oral liquid 20ml, be added in the AB-8 type macroporous adsorptive resins handled well successively with water 100ml, 20% ethanol 100ml eluting, discard eluent, reuse 50% ethanol 100ml eluting, eluent evaporate to dryness, residue adds methanol 2ml dissolving, as need testing solution.Other gets the puerarin reference substance, adds methanol and makes the solution that every 1ml contains 1mg, in contrast product solution.According to the thin layer chromatography test, draw need testing solution 6 μ l, reference substance solution 4 μ l put respectively on same silica gel g thin-layer plate, are developing solvent with chloroform-methanol-water, launch, and take out, and dry, and after the ammonia steam is smoked, inspect to ultra-violet lamp.In the test sample chromatograph, with contrast chromatograph corresponding position on, show the fluorescence speckle of same color;
(3) get the paeoniflorin reference substance, add ethanol and make the solution that every 1ml contains 1mg, product solution in contrast, test according to thin layer chromatography, draw each the 6 μ l of need testing solution under above-mentioned reference substance solution and discriminating (2) item respectively, put respectively on same silica gel g thin-layer plate, with chloroform-ethyl acetate-methanol-formic acid is developing solvent, launches, and takes out, dry, spray is with 5% vanillin sulfuric acid solution, and hot blast blows to clear spot, in the test sample chromatograph, with reference substance chromatograph relevant position on, show identical bluish violet speckle;
(4) get this oral liquid 20ml, add hydrochloric acid 3ml, heated 30 minutes to water-bath, extracted with diethyl ether 3 times are used in cooling immediately, and each 30ml merges ether solution, and low temperature volatilizes ether, and residue adds chloroform 2ml and dissolves, as need testing solution.Other gets emodin reference substance and chrysophanol reference substance, add methanol respectively and make the solution that every 1ml contains 1mg, product solution in contrast, test according to thin layer chromatography, drawing each 6 μ l of above-mentioned three kinds of solution, put respectively on same silica gel g thin-layer plate, is developing solvent with petroleum ether-Ethyl formate, launch, take out, dry, to ultra-violet lamp, inspect, in the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show identical orange-yellow fluorescence speckle, after the ammonia steam is smoked, inspect to daylight, speckle becomes redness;
(5) this oral liquid retention time in the gained chromatograph under the assay item should be consistent with the retention time of reference substance;
That checks thes contents are as follows:
Relative density should be not less than 1.05;
PH value should be 4.5-7.0;
Other should meet every regulation relevant under the mixture item;
Theing contents are as follows of assay:
According to high effective liquid chromatography for measuring;
Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; Methanol-water-phosphoric acid is mobile phase, and the detection wavelength is 280nm.Number of theoretical plate is pressed the baicalin peak and is calculated, and should be not less than 2500; It is an amount of that the preparation precision of reference substance solution takes by weighing the baicalin reference substance, adds 70% ethanol and make the solution that every 1ml contains 18 μ g, in contrast product solution;
The accurate this product 5ml that draws of the preparation of need testing solution puts in the 100ml measuring bottle, adds 70% ethanol dilution to scale, shakes up.The accurate 1.0ml that draws puts in the 10ml measuring bottle, adds 70% ethanol dilution to scale, shakes up, as need testing solution;
Accurate respectively reference substance and each the 10 μ l injection chromatograph of liquid of need testing solution drawn of algoscopy measured promptly; This oral liquid contains Radix Scutellariae must not be less than 3.0mg/ml in baicalin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101049406A CN1318059C (en) | 2005-09-22 | 2005-09-22 | Chinese medicinal formulation for treating infant lung and stomach exuberance heat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101049406A CN1318059C (en) | 2005-09-22 | 2005-09-22 | Chinese medicinal formulation for treating infant lung and stomach exuberance heat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1762455A true CN1762455A (en) | 2006-04-26 |
| CN1318059C CN1318059C (en) | 2007-05-30 |
Family
ID=36746914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101049406A Active CN1318059C (en) | 2005-09-22 | 2005-09-22 | Chinese medicinal formulation for treating infant lung and stomach exuberance heat |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1318059C (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101352534B (en) * | 2007-07-24 | 2011-07-27 | 郑秀萍 | Chinese medicinal composition, and preparation method and uses thereof |
| CN102366489A (en) * | 2011-10-26 | 2012-03-07 | 文登市口腔医院 | Chinese traditional medicine for treating acute tonsillitis |
| CN104800616A (en) * | 2015-04-07 | 2015-07-29 | 范永启 | Compound essential oil for preventing and curing stomatitis |
| CN105456385A (en) * | 2015-12-21 | 2016-04-06 | 北京同仁堂科技发展股份有限公司 | Traditional Chinese medicine composition with antipyretic effect and preparation method and application thereof |
| CN105535136A (en) * | 2015-12-21 | 2016-05-04 | 北京同仁堂科技发展股份有限公司 | A traditional Chinese medicine composition having a bacteriostasis function, a preparing method thereof and uses of the composition |
| CN106198840A (en) * | 2016-08-12 | 2016-12-07 | 成都维恒医药科技有限公司 | Developing solvent and thin-layer identification method for Chinese crude drug Radix Et Rhizoma Rhei thin-layer identification method |
| CN106806710A (en) * | 2016-11-28 | 2017-06-09 | 李元英 | A kind of traditional Chinese powder medicine for treating cough due to wind-heat evil |
| CN107462658A (en) * | 2017-07-18 | 2017-12-12 | 厦门市健康医疗大数据管理中心 | A kind of thin-layer chromatography qualitative identification method of Pueraria lobota ' Yanming ' capsules for clearing |
| CN112402516A (en) * | 2020-11-19 | 2021-02-26 | 广州一品红制药有限公司 | Preparation method and application of Qinxiang Qingjie oral liquid |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1348795A (en) * | 2001-10-30 | 2002-05-15 | 刘汉超 | Chinese medicine mixture for treating infantile infection of upper respiratory tract and pulmonitis |
| CN1306952C (en) * | 2003-05-21 | 2007-03-28 | 西安碑林药业股份有限公司 | Chinese traditional medicine for treating chronic pharyngolaryngitis and its preparing process |
-
2005
- 2005-09-22 CN CNB2005101049406A patent/CN1318059C/en active Active
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101352534B (en) * | 2007-07-24 | 2011-07-27 | 郑秀萍 | Chinese medicinal composition, and preparation method and uses thereof |
| CN102366489A (en) * | 2011-10-26 | 2012-03-07 | 文登市口腔医院 | Chinese traditional medicine for treating acute tonsillitis |
| CN102366489B (en) * | 2011-10-26 | 2013-09-18 | 刘运波 | Chinese traditional medicine for treating acute tonsillitis |
| CN104800616A (en) * | 2015-04-07 | 2015-07-29 | 范永启 | Compound essential oil for preventing and curing stomatitis |
| CN105456385A (en) * | 2015-12-21 | 2016-04-06 | 北京同仁堂科技发展股份有限公司 | Traditional Chinese medicine composition with antipyretic effect and preparation method and application thereof |
| CN105535136A (en) * | 2015-12-21 | 2016-05-04 | 北京同仁堂科技发展股份有限公司 | A traditional Chinese medicine composition having a bacteriostasis function, a preparing method thereof and uses of the composition |
| CN106198840A (en) * | 2016-08-12 | 2016-12-07 | 成都维恒医药科技有限公司 | Developing solvent and thin-layer identification method for Chinese crude drug Radix Et Rhizoma Rhei thin-layer identification method |
| CN106806710A (en) * | 2016-11-28 | 2017-06-09 | 李元英 | A kind of traditional Chinese powder medicine for treating cough due to wind-heat evil |
| CN107462658A (en) * | 2017-07-18 | 2017-12-12 | 厦门市健康医疗大数据管理中心 | A kind of thin-layer chromatography qualitative identification method of Pueraria lobota ' Yanming ' capsules for clearing |
| CN107462658B (en) * | 2017-07-18 | 2019-07-30 | 厦门市健康医疗大数据管理中心 | A kind of thin-layer chromatography qualitative identification method of Pueraria lobota ' Yanming ' capsules for clearing |
| CN112402516A (en) * | 2020-11-19 | 2021-02-26 | 广州一品红制药有限公司 | Preparation method and application of Qinxiang Qingjie oral liquid |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1318059C (en) | 2007-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102657823B (en) | Traditional Chinese medicine composition with anticancer effect and preparation method and detection method thereof | |
| CN101837065B (en) | Medicine with anti-hepatitis, anti-tumour and organism immunity improving functions and preparation method thereof | |
| CN100533140C (en) | Checking method for depression relieving and tranquilizing preparation | |
| CN1318059C (en) | Chinese medicinal formulation for treating infant lung and stomach exuberance heat | |
| CN101502579A (en) | Chinese medicinal composition for treating digestive tumor and preparation method thereof | |
| CN105744941A (en) | Ephedra extract stripped of ephedrine alkaloids, method for producing same and use of same | |
| CN102068509B (en) | Method for preparing pulsatilla chinensis (Bunge) Regel active ingredient, method for preparing preparation of pulsatilla chinensis (Bunge) Regel active ingredient and application of pulsatilla chinensis (Bunge) Regel active ingredient in preparation of antineoplastic medicament | |
| CN1817898A (en) | Use of anti-inflammatory medicine for scheelite total saponin and its saponin compound | |
| CN102100761B (en) | Plant extract composition for preventing and treating lipidmetabolic disorder and preparation method thereof | |
| CN113663029A (en) | Compound wild buckwheat rhizome composition | |
| CN102920964A (en) | Traditional Chinese medicine preparation for curing cough | |
| CN1292778C (en) | Chinese medicine composition for stopping itching and its preparing method | |
| CN101879271B (en) | Quality detection method of red tangerine peel capsule | |
| CN1785255A (en) | Method for quality control of traditional Chinese medicine prepns. | |
| CN105920199A (en) | Traditional Chinese medicinal composition for treating pulmonary infection, oral fast dissolving membrane and preparation method thereof | |
| CN105963500B (en) | Traditional Chinese medicine preparation for treating cold and preparation method and detection method thereof | |
| CN100482266C (en) | Medical composite prepared by sarcandra and oldenlandia | |
| CN1228076C (en) | Chinese drugs for treating preceded menstrual cycle and excessive menses due to blood heat | |
| CN1331522C (en) | Red tangerine peel medicine for treating sputum cough and its preparation method | |
| CN100534476C (en) | Traditional Chinese medicine composition made by isatis root and rhizoma belamcandae, and its preparation method and use | |
| CN1961898B (en) | An antitumor compound pharmaceutical composition with barbed stullcap and preparation process thereof | |
| CN1087627C (en) | Medicament for treating diabetes and its preparation method | |
| CN101073611B (en) | Medicinal composition for preventing tumor | |
| CN1775254A (en) | Medicinal preparation for treating deaf and preparing method | |
| CN1733273A (en) | Sanjin pharmaceutical preparation, preparation method and quality control method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HAN ZHIQIANG Free format text: FORMER OWNER: SUNSTONE (TANGSHAN) PHARMACY CO. LTD. Effective date: 20091225 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20091225 Address after: Torch Road, Tangshan City hi tech Development Zone, Hebei Province: 063020 Patentee after: Han Zhiqiang Address before: Torch Road, Tangshan City hi tech Development Zone, Hebei Province: 063020 Co-patentee before: Han Zhiqiang Patentee before: SUNSTONE (TANGSHAN) PHARMACEUTICAL CO.,LTD. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20100115 Address after: Hebei Tangshan City high and New Technology Development Zone Torch Road sun stone (Tangshan) Pharmaceutical Co., Ltd. zip: 063020 Co-patentee after: SUNSTONE (TANGSHAN) PHARMACEUTICAL CO.,LTD. Patentee after: Han Zhiqiang Address before: Torch Road, Tangshan City hi tech Development Zone, Hebei Province: 063020 Patentee before: Han Zhiqiang |
|
| ASS | Succession or assignment of patent right |
Owner name: SUNSTONE (TANGSHAN) PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HAN ZHIQIANG Effective date: 20101220 Free format text: FORMER OWNER: SUNSTONE (TANGSHAN) PHARMACEUTICAL CO., LTD. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 063020 SUNSTONE (TANGSHAN) PHARMACEUTICAL CO., LTD., HUOJU ROAD, NEW + HIGH TECHNOLOGY DEVELOPMENT ZONE, TANGSHAN CITY, HEBEI PROVINCE TO: 063020 NO. 139, HUOJU ROAD, HIGH-TECH. DEVELOPMENT AREA, TANGSHAN CITY, HEBEI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20101220 Address after: 063020 Torch Road, Tangshan City hi tech Development Zone, Hebei 139, China Patentee after: SUNSTONE (TANGSHAN) PHARMACEUTICAL CO.,LTD. Address before: 063020 Tangshan City Hebei hi tech Development Zone Torch Road sun stone (Tangshan) Pharmaceutical Co., Ltd. Co-patentee before: SUNSTONE (TANGSHAN) PHARMACEUTICAL CO.,LTD. Patentee before: Han Zhiqiang |
|
| ASS | Succession or assignment of patent right |
Owner name: BEIJING SUPERTRACK MEDICAL TECHNOLOGY DEVELOPMENT Free format text: FORMER OWNER: TAIYANGSHI (TANGSHAN) PHARMACEUTICAL IND. CO., LTD. Effective date: 20140620 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 063020 TANGSHAN, HEBEI PROVINCE TO: 100029 CHAOYANG, BEIJING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140620 Address after: 100029 Beijing North Third Ring Road No. 11 Beijing University of Chinese Medicine rainbow hotel room 235 Patentee after: BEIJING SUPERTRACK MEDICAL TECHNOLOGY DEVELOP CO.,LTD. Address before: 063020 Torch Road, Tangshan City hi tech Development Zone, Hebei 139, China Patentee before: SUNSTONE (TANGSHAN) PHARMACEUTICAL CO.,LTD. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160906 Address after: 510530 Guangdong city of Guangzhou Province Economic and Technological Development Zone East Road No. 6 self building Patentee after: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. Address before: 100029 Beijing North Third Ring Road No. 11 Beijing University of Chinese Medicine rainbow hotel room 235 Patentee before: BEIJING SUPERTRACK MEDICAL TECHNOLOGY DEVELOP CO.,LTD. |
|
| CB03 | Change of inventor or designer information |
Inventor after: Li Hanxiong Inventor after: Han Zhiqiang Inventor after: Jia Xiaodong Inventor after: An Deqing Inventor after: Zeng Xinglei Inventor after: Tian Ying Inventor before: Han Zhiqiang Inventor before: Jia Xiaodong Inventor before: An Deqing Inventor before: Zeng Xinglei Inventor before: Tian Ying |
|
| CB03 | Change of inventor or designer information | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221117 Address after: No.6 Dongbo Road, East District, Guangzhou Economic and Technological Development Zone, Guangdong 510000 Patentee after: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. Patentee after: GUANGDONG ZERUI PHARMACEUTICAL Co.,Ltd. Patentee after: Guangzhou Lianrui Pharmaceutical Co.,Ltd. Patentee after: Guangzhou Runlin Pharmaceutical Technology Co.,Ltd. Patentee after: Euphorbia Biological Medicine Co.,Ltd. Address before: Building 1, No. 6, Dongbo Road, Guangzhou Economic and Technological Development Zone, Guangdong Province Patentee before: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right |